메뉴 건너뛰기




Volumn 35, Issue 2, 2011, Pages 65-71

Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain;Coste-efectividad de la combinación dutasterida y tamsulosina en el tratamiento de la hiperplasia benigna de próstata en España

Author keywords

Benign prostatic hyperplasia; Combination therapy; Cost effectiveness; Dutasteride; Tamsulosin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AZASTEROID; DUTASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; SULFONAMIDE; TAMSULOSIN;

EID: 79952315017     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2010.11.008     Document Type: Article
Times cited : (19)

References (26)
  • 2
    • 0041382438 scopus 로고    scopus 로고
    • Lower urinary tract symptoms/benign prostatic hyperplasia: Maintaining symptom control and reducing complications
    • DOI 10.1016/S0090-4295(03)00480-1
    • M.P. O'Leary Lower urinary tract symptoms/benign prostatic hyperplasia: Maintaining symptom control and reducing complications Urology. 62 Suppl 1 2003 15 23 (Pubitemid 41113200)
    • (2003) Urology , vol.62 , Issue.3 SUPPL. 1 , pp. 15-23
    • O'Leary, M.P.1
  • 3
    • 70449536472 scopus 로고    scopus 로고
    • The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study
    • C.G. Roehrborn, P. Siami, J. Barkin, R. Damião, K. Major-Walker, and I. Nandi The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study Eur Urol. 57 2010 123 131
    • (2010) Eur Urol. , vol.57 , pp. 123-131
    • Roehrborn, C.G.1    Siami, P.2    Barkin, J.3    Damião, R.4    Major-Walker, K.5    Nandi, I.6
  • 6
    • 77954865889 scopus 로고    scopus 로고
    • Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: una guía práctica
    • J. Mar, F. Antoñanzas, R. Pradas, and A. Arrospide Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: una guía práctica Gac Sanit. 24 2010 209 214
    • (2010) Gac Sanit. , vol.24 , pp. 209-214
    • Mar, J.1    Antoñanzas, F.2    Pradas, R.3    Arrospide, A.4
  • 7
    • 59749086003 scopus 로고    scopus 로고
    • Modelos de Markov: una herramienta útil para el análisis farmacoeconómico
    • C. Rubio-Terres, and A. Echevarría Modelos de Markov: una herramienta útil para el análisis farmacoeconómico Pharmacoec Sp Res Art. 3 2006 71 78
    • (2006) Pharmacoec Sp Res Art. , vol.3 , pp. 71-78
    • Rubio-Terres, C.1    Echevarría, A.2
  • 8
    • 79952313056 scopus 로고    scopus 로고
    • Distribución de Severidad Clínica y Prevalencia de Criterios de Progresión en Consulta de Urología en Pacientes con Hiperplasia Benigna de Próstata en España
    • 12-15 Junio: Abstract C-41.
    • Miñana B, Layola M, Prieto M. Distribución de Severidad Clínica y Prevalencia de Criterios de Progresión en Consulta de Urología en Pacientes con Hiperplasia Benigna de Próstata en España. LXXIV Congreso Nacional de Urología. 12-15 Junio 2009: Abstract C-41.
    • (2009) LXXIV Congreso Nacional de Urología
    • Miñana, B.1    Layola, M.2    Prieto, M.3
  • 9
    • 79952317922 scopus 로고    scopus 로고
    • Disponible en
    • Datos de mortalidad de varones mayores de 60 años (2001). Disponible en: http://www.who.int/whosis/database/life-tables/life-table- process.cfm?path=whosis,life-tables&language=english
    • (2001) Datos de Mortalidad de Varones Mayores de 60 Años
  • 12
    • 79952314602 scopus 로고    scopus 로고
    • Base de datos del Medicamento del Consejo General de Colegios Oficiales de Farmacéuticos
    • Disponible en
    • Base de datos del Medicamento del Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de Especialidades Farmacéuticas. 2010. Disponible en: https://botplusweb.portalfarma.com/
    • (2010) Catálogo de Especialidades Farmacéuticas
  • 14
    • 0017347943 scopus 로고
    • Foundations of cost effectiveness analysis for health and medical practices
    • M.C. Weinstein, and W.B. Stason Foundations of cost-effective analysis for health and medical practices N Engl J Med. 296 1977 716 721 (Pubitemid 8066534)
    • (1977) New England Journal of Medicine , vol.296 , Issue.13 , pp. 716-721
    • Weinstein, M.C.1    Stason, W.B.2
  • 15
    • 0024354921 scopus 로고    scopus 로고
    • Methodology for measuring health-state preferences - Ll: Scaling methods
    • D.G. Froberg, and R.L. Kane Methodology for measuring health-state preferences - ll: scaling methods J Clin Epidemiol. 42 1998 459 471
    • (1998) J Clin Epidemiol. , vol.42 , pp. 459-471
    • Froberg, D.G.1    Kane, R.L.2
  • 16
    • 0026864403 scopus 로고
    • Comparison of the cost-effectiveness of various therapies for common prostatic disorders
    • E.A. Amin, and M. Amin Comparison of the cost-effectiveness of various therapies for common prostatic disorders Pharmacoeconomics. 1 1992 357 369
    • (1992) Pharmacoeconomics. , vol.1 , pp. 357-369
    • Amin, E.A.1    Amin, M.2
  • 17
    • 0029971556 scopus 로고    scopus 로고
    • An economic evaluation of finasteride for treatment of benign prostatic hyperplasia
    • J.F. Baladi, D. Menon, and N. Otten An economic evaluation of finasteride for treatment of benign prostatic hyperplasia Pharmacoeconomics. 9 1996 443 454 (Pubitemid 26141901)
    • (1996) PharmacoEconomics , vol.9 , Issue.5 , pp. 443-454
    • Baladi, J.-F.1    Menon, D.2    Otten, N.3
  • 18
    • 0032324250 scopus 로고    scopus 로고
    • 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A department of veterans affairs cooperative study
    • R.C. Flanigan, D.J. Reda, J.H. Wasson, R.J. Anderson, M. Abdellatif, and R.C. Bruskewitz 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A department of veterans affairs cooperative study J Urol. 160 1998 12 16
    • (1998) J Urol. , vol.160 , pp. 12-16
    • Flanigan, R.C.1    Reda, D.J.2    Wasson, J.H.3    Anderson, R.J.4    Abdellatif, M.5    Bruskewitz, R.C.6
  • 19
    • 0027567741 scopus 로고
    • Transurethral prostatectomay versus transurethral dilatiation of the prostatic urethra for benign prostatic hyperplasia: A cost-utility analysis
    • R.S. Bissonni, F.H. Lawler, and D.R. Holtgrave Transurethral prostatectomay versus transurethral dilatiation of the prostatic urethra for benign prostatic hyperplasia: A cost-utility analysis Famil Prac Res J. 13 1993 25 36
    • (1993) Famil Prac Res J. , vol.13 , pp. 25-36
    • Bissonni, R.S.1    Lawler, F.H.2    Holtgrave, D.R.3
  • 21
    • 0029921839 scopus 로고    scopus 로고
    • An estimate of the life-time cost of surgical treatment of patients with benign prostatic hyperplasia in Sweden
    • C. Ahlstrand, P. Carlsson, and B. Jonsson An estimate of the life-time costs of surgical treatment of patients with benign prostatic hyperplasia In Sweeden Scan J Urol Nephro. 30 1996 37 43 (Pubitemid 26108070)
    • (1996) Scandinavian Journal of Urology and Nephrology , vol.30 , Issue.1 , pp. 37-43
    • Ahlstrand, C.1    Carlsson, P.2    Jonsson, B.3
  • 22
    • 0029552647 scopus 로고
    • Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia
    • DOI 10.1016/S0090-4295(99)80258-1
    • F.C. Lowe, R.C. McDaniel, J.J. Chmiel, and A.L. Hillman Economic modeling to assess the costs of treatment with finsateride, terazosin, transurectal resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Urology. 46 1995 477 483 (Pubitemid 26101337)
    • (1995) Urology , vol.46 , Issue.4 , pp. 477-483
    • Lowe, F.C.1    Mcdaniel, R.L.2    Chmiel, J.J.3    Hillman, A.L.4
  • 23
    • 0031886073 scopus 로고    scopus 로고
    • An introduction to Markov modelling for economic evaluation
    • DOI 10.2165/00019053-199813040-00003
    • A. Briggs, and M. Sculpher An introduction to Markov modeling for economic evaluation Pharmacoeconomics. 13 1998 397 409 (Pubitemid 28140699)
    • (1998) PharmacoEconomics , vol.13 , Issue.4 , pp. 397-409
    • Briggs, A.1    Sculpher, M.2
  • 25
    • 0027193264 scopus 로고
    • Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem
    • A. Gafni, and S. Birch Guidelines for the adoption of new technologies: a prescription for uncontroleed growth in expenditures and how to avoid the problem CAMJ. 148 1993 913 917 (Pubitemid 23125540)
    • (1993) Canadian Medical Association Journal , vol.148 , Issue.6 , pp. 913-917
    • Gafni, A.1    Birch, S.2
  • 26
    • 51149098773 scopus 로고    scopus 로고
    • The NICE Cost-Effectiveness Threshold. What it is and what it means
    • C. McCabe, K. Claxton, and A.J. Culyer The NICE Cost-Effectiveness Threshold. What it is and what it means Pharmacoeconomics. 26 2008 733 744
    • (2008) Pharmacoeconomics. , vol.26 , pp. 733-744
    • McCabe, C.1    Claxton, K.2    Culyer, A.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.